1. Continued reduction in CVD events with LDL-C reductions to very low levels <25 mg/dL.
2. Lack of adverse events with LDL-C reduced to <25 mg/dL with PCSK9 monoclonal antibodies.
3. Unreliability of calculated LDL-C by Friedewald formula when LDL-C decreases below 50 mg/dL.
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation